GLAXO.NS — GlaxoSmithKline Pharmaceuticals Limited (Stock)

Price: $2563.4 · 1 day: +1.53% · 5 days: +0.93% · 1 month: -10.23% · YTD: +4.40%
As of 2026-10-16 09:02 UTC.

52-week range: $2088.1 – $3120.7 (currently at 46% of the range).

The brief

GLAXO.NS is in a turning up, momentum soft. $2600 is the level overhead; $2550 the first support below.

3 of 6 technical checks lean mixed.

Price vs 50-day: below
Price vs 200-day: above
50d vs 200d avg: above
MACD: bearish
RSI momentum: 16
5-day tape: +0.9%

Trend	Turning up · below 50-day & 200-day
Momentum	RSI 15.67 · neutral · MACD bearish
Trend strength	ADX 25.7 · strong trend
Location	-8.6% vs 50-day MA
52-week range	-17% from high · +22% from low
Volatility	ATR 69.85 · ~2.7%/day

Key levels

Level	Type	Distance
$2600.0 (resistance)	round	1.43%
$2650.0 (resistance)	round	3.38%
$2803.82 (resistance)	sma 50	9.38%
$2550.0 (support)	round	-0.52%
$2512.81 (support)	sma 200	-1.97%
$2500.0 (support)	round	-2.47%

Indicators

RSI (14)	15.67	MACD	-82.4918
ADX (14)	25.7	ATR (14)	69.85
50-day average	$2803.82	200-day average	$2512.81

Next earnings: 2025-07-31.

Latest GLAXO.NS news

TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations — # Summary TuHURA Biosciences, Inc. (NASDAQ: HURA) announced the appointment of Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations, effective April 7, 2026. Garofalo brings over 20 years of experience (PR Newswire, 2026-04-07)
GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) Q2 2026 Earnings Call Highlights: Navigating ... — Despite a sales decline, GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) showcases resilience with improved margins and robust specialty business growth. (GuruFocus.com, 2025-11-13)
India's elderly need more than respect, they need urgent policy focus — India faces a rapidly aging population crisis, with nearly 15% expected to be over 60 by 2036 and reaching 347 million seniors by 2050, creating significant healthcare system pressures and economic implications. Currentl (Economic Times, 2025-09-16)
GSK Licenses Shigella Vaccine to Bharat Biotech — GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech. The licensing is part of the company’s effort to get th (Insider Monkey, 2025-06-17)
Patents and economies of scale support Pfizer's wide moat — Patent-protected drugs provide strong pricing power, enabling returns on invested capital. (GuruFocus.com, 2025-06-07)
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue? — Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. (Zacks, 2025-06-05)
Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue? — Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. (Zacks, 2025-05-30)
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? — Here is how GSK (GSK) and Amarin (AMRN) have performed compared to their sector so far this year. (Zacks, 2025-05-29)

Explore more

Interactive GLAXO.NS chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs